Consumers and their doctors all know about LDL and the need to lower the so-called bad cholesterol. But what about the treatments beyond those that lower LDL? James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells host Bruce Japsen about new developments in treating and managing cholesterol beyond lowering LDL.
Beyond LDL: New Treatment Options to Manage Lipids
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Consumers and their doctors all know about LDL and the need to lower the so-called bad cholesterol. But what about the treatments beyond those that lower LDL? James Stolzenbach, who oversees clinical research in the area of dyslipidemia and renal drug development at Abbott Laboratories, tells host Bruce Japsen about new developments in treating and managing cholesterol beyond lowering LDL.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
Level Up Your Skills: Tailoring Management of HF
0.75 credits
<p>Level Up Your Skills: Tailoring Management of HF</p>
CME/CE
Personalizing Care Within the RCC Treatment Paradigm
1.00 credits
<p>Personalizing Care Within the RCC Treatment Paradigm</p>
NeuroFrontiers
Navigating Myasthenia Gravis in Adolescents and Young Adults
<p>Navigating Myasthenia Gravis in Adolescents and Young Adults</p>
Clinician's Roundtable
Challenges in AI-Driven Dermatology: Understanding Current Limitations
<p>Challenges in AI-Driven Dermatology: Understanding Current Limitations</p>
Cardiology
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
<p>Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?